Shilpa Medicare Share Price
Sector: Biotechnology & Drugs
861.20 -8.30 (-0.95%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
850.00
Today’s High
879.00
52 Week Low
530.50
52 Week High
1003.20
863.95 +6.15 (0.72%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
858.00
Today’s High
879.00
52 Week Low
555.00
52 Week High
1000.00
Key Metrics
- Market Cap (In Cr) 8421.75
- Beta 0.41
- Div. Yield (%) 0.12
- P/B 3.56
- TTM P/E 82.41
- Sector P/E 22.43
- D/E 0
- Open Price 868
- Prev Close 869.5
Shilpa Medicare Analysis
Price Analysis
-
1 Week-1.87%
-
3 Months30.23%
-
6 Month12.35%
-
YTD5.94%
-
1 Year53.67%
Risk Meter
- 52% Low risk
- 52% Moderate risk
- 52% Balanced Risk
- 52% High risk
- 52% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 2
- Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Hold
- 1
- 1
- 1
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Shilpa Medicare News
Q4 results today: GIC, Aurobindo Pharma, Sumitomo Chemical, Nazara Tech, more
1 min read . 26 May 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 23 May 2025Best stock recommendations today: MarketSmith India's top picks for 16 May
4 min read . 16 May 2025Shilpa Medicare Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 1286.41
- Selling/ General/ Admin Expenses Total
- 292.71
- Depreciation/ Amortization
- 112.99
- Other Operating Expenses Total
- 266.28
- Total Operating Expense
- 1110.44
- Operating Income
- 175.98
- Net Income Before Taxes
- 122.33
- Net Income
- 78.29
- Diluted Normalized EPS
- 9.89
- Period
- 2025
- Total Assets
- 3310.71
- Total Liabilities
- 938.47
- Total Equity
- 2372.24
- Tangible Book Valueper Share Common Eq
- 184.84
- Period
- 2025
- Cashfrom Operating Activities
- 132.18
- Cashfrom Investing Activities
- -199.08
- Cashfrom Financing Activities
- 62.65
- Net Changein Cash
- -3.23
- Period
- 2024
- Total Revenue
- 1151.6
- Selling/ General/ Admin Expenses Total
- 394.97
- Depreciation/ Amortization
- 107.87
- Other Operating Expenses Total
- 16.45
- Total Operating Expense
- 1017.81
- Operating Income
- 133.79
- Net Income Before Taxes
- 54.34
- Net Income
- 31.87
- Diluted Normalized EPS
- 3.22
- Period
- 2024
- Total Assets
- 3093.2
- Total Liabilities
- 1284.51
- Total Equity
- 1808.69
- Tangible Book Valueper Share Common Eq
- 149.91
- Period
- 2024
- Cashfrom Operating Activities
- 136.67
- Cashfrom Investing Activities
- -166.58
- Cashfrom Financing Activities
- 46.77
- Net Changein Cash
- 12.68
- Period
- 2023
- Total Revenue
- 1050.11
- Selling/ General/ Admin Expenses Total
- 406.32
- Depreciation/ Amortization
- 95.5
- Other Operating Expenses Total
- 19.06
- Total Operating Expense
- 1057.08
- Operating Income
- -6.96
- Net Income Before Taxes
- -38.28
- Net Income
- -32.48
- Diluted Normalized EPS
- -3.72
- Period
- 2023
- Total Assets
- 2903.93
- Total Liabilities
- 1120.65
- Total Equity
- 1783.28
- Tangible Book Valueper Share Common Eq
- 149.43
- Period
- 2023
- Cashfrom Operating Activities
- 179.92
- Cashfrom Investing Activities
- -232.61
- Cashfrom Financing Activities
- 45.8
- Net Changein Cash
- -6.55
- Period
- 2022
- Total Revenue
- 1145.52
- Selling/ General/ Admin Expenses Total
- 425.8
- Depreciation/ Amortization
- 79.8
- Other Operating Expenses Total
- 16.47
- Total Operating Expense
- 1017.92
- Operating Income
- 127.61
- Net Income Before Taxes
- 102.26
- Net Income
- 60.66
- Diluted Normalized EPS
- 6.75
- Period
- 2022
- Total Assets
- 2875.5
- Total Liabilities
- 1053.3
- Total Equity
- 1822.19
- Tangible Book Valueper Share Common Eq
- 158.73
- Period
- 2022
- Cashfrom Operating Activities
- 105.13
- Cashfrom Investing Activities
- -285.5
- Cashfrom Financing Activities
- 82.86
- Net Changein Cash
- -97.51
- Period
- 2021
- Total Revenue
- 901.13
- Selling/ General/ Admin Expenses Total
- 352.74
- Depreciation/ Amortization
- 53.98
- Other Operating Expenses Total
- 21.09
- Total Operating Expense
- 721.98
- Operating Income
- 179.15
- Net Income Before Taxes
- 195.05
- Net Income
- 147.78
- Diluted Normalized EPS
- 12.59
- Period
- 2021
- Total Assets
- 2632.37
- Total Liabilities
- 1153.7
- Total Equity
- 1478.67
- Tangible Book Valueper Share Common Eq
- 137.55
- Period
- 2021
- Cashfrom Operating Activities
- 47.07
- Cashfrom Investing Activities
- -404.28
- Cashfrom Financing Activities
- 436.37
- Net Changein Cash
- 79.03
- Period
- 2020
- Total Revenue
- 907.91
- Selling/ General/ Admin Expenses Total
- 314.9
- Depreciation/ Amortization
- 43.78
- Other Operating Expenses Total
- 13.55
- Total Operating Expense
- 735.91
- Operating Income
- 172
- Net Income Before Taxes
- 188.05
- Net Income
- 156.15
- Diluted Normalized EPS
- 19.15
- Period
- 2020
- Total Assets
- 1986.13
- Total Liabilities
- 656.77
- Total Equity
- 1329.36
- Tangible Book Valueper Share Common Eq
- 132.29
- Period
- 2020
- Cashfrom Operating Activities
- 123.72
- Cashfrom Investing Activities
- -288.85
- Cashfrom Financing Activities
- 175.5
- Net Changein Cash
- 10.2
- Period
- 2019
- Total Revenue
- 733.39
- Selling/ General/ Admin Expenses Total
- 245.4
- Depreciation/ Amortization
- 42.06
- Other Operating Expenses Total
- 10.98
- Total Operating Expense
- 639.11
- Operating Income
- 94.28
- Net Income Before Taxes
- 135.68
- Net Income
- 112.26
- Diluted Normalized EPS
- 15.75
- Period
- 2019
- Total Assets
- 1610.02
- Total Liabilities
- 412.44
- Total Equity
- 1197.58
- Tangible Book Valueper Share Common Eq
- 123.81
- Period
- 2019
- Cashfrom Operating Activities
- 138.76
- Cashfrom Investing Activities
- -188.15
- Cashfrom Financing Activities
- 10.06
- Net Changein Cash
- -39.47
- Period
- 2025-03-31
- Total Revenue
- 330.8
- Selling/ General/ Admin Expenses Total
- 70.93
- Depreciation/ Amortization
- 28.79
- Other Operating Expenses Total
- 78.64
- Total Operating Expense
- 310.91
- Operating Income
- 19.89
- Net Income Before Taxes
- 15.27
- Net Income
- 14.51
- Diluted Normalized EPS
- 4.2
- Period
- 2025-03-31
- Total Assets
- 3310.71
- Total Liabilities
- 938.47
- Total Equity
- 2372.24
- Tangible Book Valueper Share Common Eq
- 184.84
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 132.18
- Cashfrom Investing Activities
- -199.08
- Cashfrom Financing Activities
- 62.65
- Net Changein Cash
- -3.23
- Period
- 2024-12-31
- Total Revenue
- 319.32
- Selling/ General/ Admin Expenses Total
- 73.49
- Depreciation/ Amortization
- 28.81
- Other Operating Expenses Total
- 74.13
- Total Operating Expense
- 267.43
- Operating Income
- 51.88
- Net Income Before Taxes
- 41.61
- Net Income
- 31.78
- Diluted Normalized EPS
- 3.25
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 343.8
- Selling/ General/ Admin Expenses Total
- 76.16
- Depreciation/ Amortization
- 28.28
- Other Operating Expenses Total
- 59.65
- Total Operating Expense
- 286.07
- Operating Income
- 57.72
- Net Income Before Taxes
- 36.77
- Net Income
- 17.94
- Diluted Normalized EPS
- 1.86
- Period
- 2024-09-30
- Total Assets
- 3117.33
- Total Liabilities
- 789.45
- Total Equity
- 2327.88
- Tangible Book Valueper Share Common Eq
- 184.39
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 105.29
- Cashfrom Investing Activities
- -107.39
- Cashfrom Financing Activities
- -8.47
- Net Changein Cash
- -13.25
- Period
- 2024-06-30
- Total Revenue
- 292.51
- Selling/ General/ Admin Expenses Total
- 72.14
- Depreciation/ Amortization
- 27.11
- Other Operating Expenses Total
- 53.96
- Total Operating Expense
- 246.02
- Operating Income
- 46.49
- Net Income Before Taxes
- 28.68
- Net Income
- 14.06
- Diluted Normalized EPS
- 1.46
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 291.97
- Selling/ General/ Admin Expenses Total
- 66.45
- Depreciation/ Amortization
- 26.63
- Other Operating Expenses Total
- 58.11
- Total Operating Expense
- 242.13
- Operating Income
- 49.84
- Net Income Before Taxes
- 27.71
- Net Income
- 24.5
- Diluted Normalized EPS
- 2.19
- Period
- 2024-03-31
- Total Assets
- 3093.2
- Total Liabilities
- 1284.51
- Total Equity
- 1808.69
- Tangible Book Valueper Share Common Eq
- 149.91
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 136.67
- Cashfrom Investing Activities
- -166.58
- Cashfrom Financing Activities
- 46.77
- Net Changein Cash
- 12.68
- Period
- 2023-12-31
- Total Revenue
- 286.48
- Selling/ General/ Admin Expenses Total
- 69.07
- Depreciation/ Amortization
- 26.71
- Other Operating Expenses Total
- 54.95
- Total Operating Expense
- 247.25
- Operating Income
- 39.24
- Net Income Before Taxes
- 14.17
- Net Income
- 4.58
- Diluted Normalized EPS
- 0.53
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Shilpa Medicare Technical
Moving Average
SMA
- 5 Day871.23
- 10 Day906.51
- 20 Day911.81
- 50 Day788.75
- 100 Day726.82
- 300 Day780.29
Shilpa Medicare Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Marksans Pharma
- 253.15
- 6.05
- 2.45
- 358.5
- 158.25
- 11476.49
- Procter & Gamble Health
- 5905.15
- 28.85
- 0.49
- 6107.55
- 4912.3
- 9888.51
- Shilpa Medicare
- 861.2
- -8.3
- -0.95
- 1003.2
- 530.5
- 8421.75
- Strides Pharma Science
- 896.4
- 10.3
- 1.16
- 906.9
- 412.71
- 8210.97
- Aarti Pharmalabs
- 859.25
- -13
- -1.49
- 948.8
- 521
- 7777.53
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Marksans Pharma
- 29.41
- 4.54
- 18.54
- 14.58
- Procter & Gamble Health
- 44.62
- 18.06
- -
- -
- Shilpa Medicare
- 86.77
- 3.54
- 3.27
- 5.17
- Strides Pharma Science
- 23.26
- 3.2
- -1.22
- -1.07
- Aarti Pharmalabs
- 29.04
- 3.98
- -
- -
Shilpa Medicare Shareholding
Shareholding Pattern
*Promoter pledging: 3.5%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results & Final Dividend
- 10-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 23-Jun-23
- Rights issue of Equity Shares
- 25-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 15-Mar-24
- 12-Feb-24
- POM
- 07-Feb-24
- 08-Jan-24
- POM
- 29-Sept-23
- 04-Sept-23
- AGM
- 30-Aug-23
- 31-Jul-23
- POM
- 01-Aug-23
- 30-Jun-23
- POM
- 27-May-22
- 26-Apr-22
- COM
- 16-Mar-22
- 14-Feb-22
- POM
- -
- 08-Aug-24
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 26-May-25
- -
- -
- 1
- 23-May-22
- -
- 19-Sept-22
- 1.1
- 31-May-21
- -
- 20-Sept-21
- 1.1


